Nilotinib monohydrochloride monohydrate是一种可有效抑制BCR-ABL及其突变体的二代酪氨酸激酶抑制剂。
|
英文别名 (English Synonym) |
Nilotinib monohydrochloride monohydrate |
|
中文名称 (Chinese Name) |
尼洛替尼盐酸盐一水合物 |
|
靶点 (Target) |
Bcr-Abl |
|
通路 (Pathway) |
TGF-β/Smad |
|
CAS号 (CAS NO.) |
923288-90-8 |
|
分子式 (Formula) |
C28H25ClF3N7O2 |
|
分子量 (Molecular Weight) |
583.99 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Weisberg E, Catley L, Wright RD, Moreno D, Banerji L, Ray A, Manley PW, Mestan J, Fabbro D, Jiang J, Hall-Meyers E, Callahan L, DellaGatta JL, Kung AL, Griffin JD. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1,109(5):2112-20. doi: 10.1182/blood-2006-06-026377. Epub 2006 Oct 26. PMID: 17068153, PMCID: PMC1801049.[2]Sako H, Fukuda K, Saikawa Y, Nakamura R, Takahashi T, Wada N, Kawakubo H, Takeuchi H, Ohmori T, Kitagawa Y. Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells. PLoS One. 2014 Sep 15,9(9):e107613. doi: 10.1371/journal.pone.0107613. PMID: 25221952, PMCID: PMC4164645.
